Table 2.
Baseline characteristics of the included study subjects
| Study/first author | Treatment group | age. Yrs | Male, % | BMI, kg/m2 | SBP, mm Hg | DBP, mm Hg | serum creatinine, umol/L | serum K, mEq/L |
|---|---|---|---|---|---|---|---|---|
| Observational uncontrolled study | ||||||||
| Ouzen et al | Spironoclatone | 65±11 | 40 | NR | 152±2 | 86±2 | NR | NR |
| Nishizaka et al | Spironoclatone | 55±12 | 40.7 | 33.6±8.7 | 163 ±18 | 91±14 | NR | 4.0±0.5 |
| Chapman et al | Spironoclatone | 63.5±8.4 | 77 | 29.4±4.6 | 156.9±18 | 85.3±11.5 | 99 | 4.18±0.5 |
| Lane et al | Spironoclatone | 62.5±12.1 | 31.9 | NR | 182.3±23.2 | 94.9±18.5 | 88.7 | 4.3±0.5 |
| Souza et al | Spironoclatone | 62±10 | 27.6 | 30.2±5.1 | 169±27 | 92±18 | 70 | 4.2±0.5 |
| Randomized controlled study | ||||||||
| Vaclavik et al | Spironoclatone | 61.4±9.6 | 67.3 | 32.3±5.1 | 154.9±10.4 | 92.6±10.7 | 81 | 4.2±0.5 |
| Placebo | 60.1±9.4 | 57.1 | 32.3±5.3 | 153.5±12 | 90.6±10.9 | 83 | 4.2±0.5 | |
| Oxlund et al | Spironoclatone | 62.9±7.1 | 75 | 32 (25 to 43) | 144±15 | 79±11 | 81.2 | 3.9±0.4 |
| Placebo | 63.9±6.9 | 78 | 31.5 (26 to 43) | 139±15 | 76±8 | 79 | 3.8±0.3 | |
| Abolghasmi et al | Spironoclatine | 49±13,2 | 53 | 31.2±4.3 | 171±10 | 95±4 | 2.2±0.8 mg/dL | 4.3±0.8 |
| Placebo | 50±10.1 | 54.5 | 30.0±3.2 | 170±10 | 93±5 | 2.3±0.6 mg/dL | 4.5±0.6 | |